12Feb/14

FDA looks at possible heart failure link with AZ's Onglyza – PharmaTimes


Drug Discovery & Development

FDA looks at possible heart failure link with AZ’s Onglyza
PharmaTimes
The agency will review Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin/metformin) after a study published in the New England Journal of Medicine reported an increased rate of hospitalisation for heart failure with use of the drugs. The FDA
FDA Investigating Heart Failure Risk Linked To OnglyzaForbes
FDA to probe saxagliptin’s heart failure riskFamily Practice News Digital Network
FDA Investigating Heart Failure Risks with SaxagliptinDrug Discovery & Development
HealthDay
all 34 news articles »
12Feb/14

Revealed – the biological 'switch' that causes fatty liver disease – India.Com Health


India.Com Health

Revealed – the biological ‘switch’ that causes fatty liver disease
India.Com Health
Liver disease In major find, scientists have discovered a biological switch that regulates a protein that causes fatty liver disease. ‘We have learned how the body finely tunes levels of a protein called SCAP that is required to turn on fat production

and more »